Navigation Links
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
Date:11/20/2008

SAN MARINO, Calif., Nov. 20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth.

Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies. Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy. These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Rexin-G and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at http://www.epeiusbiotech.com .

*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
2. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
3. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
4. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
5. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
6. New Insight Into the Controls on a Go-To Enzyme
7. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
8. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
9. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014   Hospira, Inc. (NYSE: ... and infusion technologies, today announced that the company will ... on Wednesday, Jan. 14, 2015, in San Francisco.  ... at 10:30 a.m. Pacific time on Wednesday, Jan. 14, ... through a live audiocast accessible via the Investor Relations ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ( ... of equipment for the testing of marijuana potency ... the new Luminary™ Profiler, the industry,s first product ... in a cost-effective, portable unit. Designed ... needs of the cannabis industry, the Luminary™ Profiler ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... Pa., June 25, 2007 /PRNewswire-FirstCall/ --,Genaera Corporation ... of trodusquemine (MSI-1436) for the treatment of ... (ADA) 67th,Scientific Sessions, June 22-25 in Chicago, ... lead author of Abstract #1801-P,presented, "Trodusquemine is ...
... blood sugar reductions seen across range of,patient populations, ... high risk of developing diabetes , * Galvus ... efficacy in combination with commonly used diabetes,medicines , ... studies showing,incidence of side effects similar to placebo ...
Cached Medicine Technology:Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 2Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 3Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 4New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 2New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 3New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 4New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 5New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 6
(Date:12/21/2014)... California (PRWEB) December 21, 2014 Serious ... search for Vintage 1967 Jm Morrison and the Doors International ... posters. This would also be the only time that ... concert was on Nov. 25, 1967. According to Hawley, ... D.C. They did play the Alexandria Roller Rink earlier ...
(Date:12/21/2014)... 2014 Theme and plugin ... intro plugin for Final Cut Pro X entitled ProMotion. ... and more with absolute ease.” Said Christiana Austin, CEO ... tools needed to easily animate their media inside FCPX.” ... X users to animate pictures, videos, logos, and more ...
(Date:12/21/2014)... 2014 Concept Plus, LLC. a SDB ... in Fairfax, VA., today announced it has been recognized ... list, which ranks the fastest growing government contracting small businesses ... 2013. , This is the first year that Concept Plus, ... 20 with a 95.92% compound annual growth rate. “For Concept ...
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection of sweet ... occasion dresses for the coming new year. , ... for global women. Now, all the models on its ... off. Among the new items, the model of 10986064 ... very popular. What’s more, Weddingshe.com also provides a fast ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The print ... Post, with a distribution of approximately 160,000 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with the ladies of CTV’s The ...
Breaking Medicine News(10 mins):Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2
... Eularis, will be delivering a MasterClass on how to tell if you are making ... WHAT: MasterClass on the latest techniques, strategies and analysis, ... measure financial impact of sales, ... WHERE: 1 Northumberland Avenue, Trafalgar Square. London, , ...
... economic conditions and the unknown effect of healthcare ... Milliman, Inc., one of the premier global ... total medical spending for its "typical American family ... While cost trends are decelerating for the third-straight ...
... Calif., May 18 Fate Therapeutics, Inc. ... the Company,s executive team with the addition of Pratik ... With more than a decade of clinical development ... trials of Stem Cell Modulators (SCMs), small molecules and ...
... show promise for better protection against flu , , MONDAY, ... virus-like particles (VLPs) could provide stronger and longer-lasting protection ... Even better, VLP vaccines, which can be grown in ... twice as quickly as conventional vaccines, according to research ...
... about vaginal dryness and pain and are reluctant to ... international survey presented today at the European Congress on ... over a third (39 percent) of post-menopausal women experience ... women who have recently experienced vaginal dryness and pain ...
... in Clinical Trials and Population Health MonitoringLINCOLN, R.I., May 18 ... well-being as a good night,s sleep. Yet millions of us ... -- suffer from chronic sleep problems or disorders. Every year, ... or insufficient sleep and disease. Now there is a simple, ...
Cached Medicine News:Health News:MEDIA ALERT - Eularis to Hold Pharmaceutical Marketing ROI MasterClass in London 2Health News:Milliman Indicates 2009 Medical Cost for 'American family of four' Exceeds $16,700 Based on 7.4% Cost Increase 2Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 2Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 3Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 4Health News:New Methods Could Speed Production of Flu Vaccines 2Health News:7 out of 10 women too embarrassed to discuss vaginal dryness and pain with their physician 2Health News:QualityMetric Offers Way to Measure the Impact of Sleep Problems on Individuals and Groups 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: